MediWound Ltd. (MDWD) Research Coverage Started at Cowen and Company
Cowen and Company assumed coverage on shares of MediWound Ltd. (NASDAQ:MDWD) in a research report released on Thursday morning, Marketbeat reports. The brokerage issued an outperform rating and a $9.00 price objective on the biopharmaceutical company’s stock.
Several other research firms have also recently issued reports on MDWD. SunTrust Banks, Inc. reissued a buy rating on shares of MediWound in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of MediWound from a strong sell rating to a hold rating in a research note on Wednesday, August 2nd. Jefferies Group LLC set a $10.00 target price on shares of MediWound and gave the stock a buy rating in a research report on Friday, August 25th. Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $10.00 target price on shares of MediWound in a research report on Monday, September 18th. Finally, ValuEngine downgraded shares of MediWound from a sell rating to a strong sell rating in a research note on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $9.15.
MediWound (MDWD) opened at 5.35 on Thursday. The firm’s 50 day moving average price is $6.30 and its 200-day moving average price is $6.53. The stock’s market cap is $117.45 million. MediWound has a 12-month low of $4.25 and a 12-month high of $8.25.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The company’s revenue for the quarter was up 93.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.34) earnings per share. Equities research analysts anticipate that MediWound will post ($0.76) earnings per share for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Migdal Insurance & Financial Holdings Ltd. lifted its stake in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares during the period. Wells Fargo & Company MN increased its position in MediWound by 23.5% during the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after purchasing an additional 12,522 shares during the period. Renaissance Technologies LLC increased its position in MediWound by 1.7% during the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares during the period. Finally, Wellington Management Group LLP increased its position in MediWound by 11.0% during the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after purchasing an additional 213,745 shares during the period. Hedge funds and other institutional investors own 19.55% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.